Reid Merryman, MD, on Potential Clinical Designs with MRD-Guidance for Patients with DLBCL

Video

Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.

Reid Merryman, MD, of the Dana-Farber Cancer Institute, spoke with CancerNetwork® about the detailed the future potential research building off an oral presentation investigating the prognostic value of circulating tumor DNA among patients with diffuse large B-cell lymphoma (DLBCL) from the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.

Transcription:

Yeah, I think you can think of different potential clinical trial designs. So, I think, The data that I presented at ASH suggests that there’s this high-risk patient population, but I don’t think we’re quite ready yet to use this in the clinical setting. I think the next step would be a clinical trial that would use MRD [minimal residual disease] to guide therapy for patients with relapsed or refractory DLBCL. So, You can imagine collecting samples for patients after salvage chemotherapy and directing MRD-negative patients to transplant and MRD-positive patients to an alternative treatment, for example CAR [chimeric antigen receptor] T-cell therapy, as part of a clinical trial.

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content